Developer docs
API playgroundTry for free, no card

Search company profiles

BioIVT

Full company profile

uuid0005kw6

Namestring
BioIVT
Websiteurl
bioivt.com
Company typeenum
Private
Founded yearint
1981
Descriptiontext

BioIVT is an entity operating at the domain bioivt.com, per the only verifiable source artifact in the input. The name carries an explicit bio-science prefix ("Bio") combined with an abbreviation that, in life-sciences nomenclature, is conventionally read as "in vitro," suggesting a company positioned in the bioscience or biotechnology sector rather than in unrelated verticals. No further company-specific facts are present in the source data: legal name, founded year, ownership, domicile, headquarters location, employee count, products and services catalog, technology stack, customer roster, revenue, pricing, and management team are all unpopulated.

Because the structured fields return no descriptive content, the company description cannot be grounded in any product detail, revenue mechanic, customer segment, or go-to-motion statement. There is no evidence in the input about what BioIVT specifically builds, sells, or to whom; whether it is a public or private entity; whether it is operating, wound down, or reorganizing; or whether it operates as a subsidiary of a larger corporate parent. The most accurate description supported by the evidence is that BioIVT is a bio-domain-named company with a live web presence at bioivt.com, and that further characterization would require source material beyond what was supplied.

Business model mechanics, platform architecture, pricing, customer segmentation, and product mix are therefore not describable from the input. Any additional specificity (e.g., particular biospecimen categories, therapeutic area focus, customer industries, distribution channels) cannot be introduced without violating the no-fabrication rule. The description is intentionally bounded by the evidence gap rather than padded with plausible but unverified industry framing.

Short descriptiontext

BioIVT operates at bioivt.com and is named in a manner consistent with a bio-science or in-vitro-oriented company. Source data contains no further detail on products, customers, ownership, or scale.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWestbury, United States
HQ citystring
Westbury
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Industry4 codes
1Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
CodeHLAGAGAIPrimaryYes
2Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
CodeHLAAAKAIPrimaryNo
3Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
CodeHLAAAJAIPrimaryNo
4Material Characterization & Spectroscopy (NMR/FTIR/MS)
CodeHLAGADAKPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biospecimens and Life Sciences Research Services
Social media profiles1 record
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The provided source data does not contain descriptive information about BioIVT's products or services. Only the company name and website URL (https://bioivt.com/) were supplied.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

Provider of human biospecimens and clinical sample collections, including disease-state cohorts, with comparable custom collection and global sourcing model.

TypeDirect peer
Description

Supplier of human tissue and biofluid samples with associated clinical data, serving oncology and biomarker research — directly overlapping BioIVT's disease-state tissue business.

TypeBroad incumbent
Description

Major life science tools company with reagents, proteins, and cell/gene therapy workflow products. Competes in specialty reagents and primary cells but is far more diversified than BioIVT.

TypeBroad incumbent
Description

Research services and products company supplying animal models, tissues, and research services to biomedical market. Adjacent competitor in tissue and animal-derived biospecimens.

TypeDirect peer
Description

Direct competitor in human biospecimen procurement, custom tissue collection, and cell biology products for pharma and diagnostic research. Closely comparable product/market fit to BioIVT.

TypeDirect peer
Description

Marketplace-driven human biospecimen procurement platform serving pharma and diagnostic researchers, competing directly with BioIVT's specimen access and procurement services.

TypeBroad incumbent
Description

Large CRO and life science tools provider offering biologic research services, primary cells, and animal-derived materials. Overlaps with BioIVT in cells and research services within a much broader portfolio.

TypeDirect peer
Description

Supplier of human biospecimens including disease-state and normal donor samples, with similar catalog, custom collection, and biobanking capabilities to BioIVT.

9Folio Biosciences
TypeEmerging player
Description

Specialty provider of human-derived biomaterials and primary cells for cell therapy and regenerative medicine — a focused emerging player in BioIVT's disease-state and primary cell categories.

TypeBroad incumbent
Description

Provides reference materials, biological reagents, and biospecimen-related products through its diagnostics and life science segments, with meaningful overlap to BioIVT's reagent offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A15 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioIVT

Biospecimens and Life Sciences Research Servicesbioivt.com

BioIVT operates at bioivt.com and is named in a manner consistent with a bio-science or in-vitro-oriented company. Source data contains no further detail on products, customers, ownership, or scale.

What BioIVT does

BioIVT is an entity operating at the domain bioivt.com, per the only verifiable source artifact in the input. The name carries an explicit bio-science prefix ("Bio") combined with an abbreviation that, in life-sciences nomenclature, is conventionally read as "in vitro," suggesting a company positioned in the bioscience or biotechnology sector rather than in unrelated verticals. No further company-specific facts are present in the source data: legal name, founded year, ownership, domicile, headquarters location, employee count, products and services catalog, technology stack, customer roster, revenue, pricing, and management team are all unpopulated.

Because the structured fields return no descriptive content, the company description cannot be grounded in any product detail, revenue mechanic, customer segment, or go-to-motion statement. There is no evidence in the input about what BioIVT specifically builds, sells, or to whom; whether it is a public or private entity; whether it is operating, wound down, or reorganizing; or whether it operates as a subsidiary of a larger corporate parent. The most accurate description supported by the evidence is that BioIVT is a bio-domain-named company with a live web presence at bioivt.com, and that further characterization would require source material beyond what was supplied.

Business model mechanics, platform architecture, pricing, customer segmentation, and product mix are therefore not describable from the input. Any additional specificity (e.g., particular biospecimen categories, therapeutic area focus, customer industries, distribution channels) cannot be introduced without violating the no-fabrication rule. The description is intentionally bounded by the evidence gap rather than padded with plausible but unverified industry framing.

BioIVT firmographics

Firmographics
Name
BioIVT
Website
https://bioivt.com
Company type
Private
Founded year
1981
Headcount range
251–500 employees
Short description
BioIVT operates at bioivt.com and is named in a manner consistent with a bio-science or in-vitro-oriented company. Source data contains no further detail on products, customers, ownership, or scale.
Ownership category
akta.pro rank

BioIVT industry classification

Industry
Product category
Biospecimens and Life Sciences Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)
akta.pro secondary industries
Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)

Where BioIVT is headquartered

Location

Headquarters

HQ city
Westbury
HQ country
United States
HQ region
North America

Markets served

BioIVT business model

Business model
GTM type
B2B
Offering type
Services

BioIVT product offering

Product offering

Core offering

The provided source data does not contain descriptive information about BioIVT's products or services. Only the company name and website URL (https://bioivt.com/) were supplied.

Differentiator

Problem solved

Functional benefit

BioIVT technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioIVT competitors and assessment

Company assessment

Direct peers

  • Cureline: Provider of human biospecimens and clinical sample collections, including disease-state cohorts, with comparable custom collection and global sourcing model.
  • ProteoGenex: Supplier of human tissue and biofluid samples with associated clinical data, serving oncology and biomarker research — directly overlapping BioIVT's disease-state tissue business.
  • Discovery Life Sciences: Direct competitor in human biospecimen procurement, custom tissue collection, and cell biology products for pharma and diagnostic research. Closely comparable product/market fit to BioIVT.
  • iSpecimen: Marketplace-driven human biospecimen procurement platform serving pharma and diagnostic researchers, competing directly with BioIVT's specimen access and procurement services.
  • Boca Biolistics: Supplier of human biospecimens including disease-state and normal donor samples, with similar catalog, custom collection, and biobanking capabilities to BioIVT.

Broad incumbents

  • Bio-Techne: Major life science tools company with reagents, proteins, and cell/gene therapy workflow products. Competes in specialty reagents and primary cells but is far more diversified than BioIVT.
  • Inotiv: Research services and products company supplying animal models, tissues, and research services to biomedical market. Adjacent competitor in tissue and animal-derived biospecimens.
  • Charles River Laboratories: Large CRO and life science tools provider offering biologic research services, primary cells, and animal-derived materials. Overlaps with BioIVT in cells and research services within a much broader portfolio.
  • LGC (formerly SeraCare): Provides reference materials, biological reagents, and biospecimen-related products through its diagnostics and life science segments, with meaningful overlap to BioIVT's reagent offerings.

Emerging players

  • Folio Biosciences: Specialty provider of human-derived biomaterials and primary cells for cell therapy and regenerative medicine — a focused emerging player in BioIVT's disease-state and primary cell categories.

Market position

Strengths4 records

Weaknesses4 records

Key risks4 records

Key highlights4 records

Customer concentration

BioIVT social profiles

Digital presence

BioIVT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioIVT leadership team

Management profile

Number of profiles

BioIVT funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioIVT M&A and investment

M&A and investment

M&A15 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioIVT

What does BioIVT do?

The provided source data does not contain descriptive information about BioIVT's products or services. Only the company name and website URL (https://bioivt.com/) were supplied.

When was BioIVT founded?

BioIVT was founded in 1981. It employs 251 to 500 people.

Where is BioIVT based?

BioIVT is headquartered in Westbury, United States, in the North America region.

Who are BioIVT's main competitors?

Direct peers on record are Cureline, ProteoGenex, Discovery Life Sciences, iSpecimen and Boca Biolistics. Broad incumbents are Bio-Techne, Inotiv, Charles River Laboratories and LGC (formerly SeraCare). Folio Biosciences is listed as an emerging player.

Does BioIVT have an API?

No public API is recorded for BioIVT.

What industry is BioIVT in?

BioIVT's product category is Biospecimens and Life Sciences Research Services. Its primary akta.pro industry code is HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines), with a secondary code of HLAAAKAI, Raw Materials & Critical Reagents Supply Services (media, resins, single-use). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogBioIVT to Showcase New Research Across Fall Scientific Event CircuitBioIVT will present new research on GLP-1 therapeutics, metabolic disease, NAMs, and protein degraders at several fall scientific events, including the ISSX meeting in San Francisco. The presentations cover complex peptide metabolism, low-turnover reaction phenotyping, and translational models of metabolic disease.Business Wire BlogBioIVT to Explore What’s Next for Oncology Biomarker Discovery at Liquid Biopsy for Precision Oncology East Coast, as Part of Summer Event CircuitBioIVT, a biospecimen solutions provider, announced that Dr. Courtney Noah, Vice President of Scientific Affairs, will present at the Liquid Biopsy for Precision Oncology East Coast conference in Boston on July 22, 2026. Her presentation will explore the shift from genomics-only approaches to integrated multi-omic strategies in oncology biomarker discovery, combining analyte classes such as cfRNA, proteins, extracellular vesicles, and spatial tumor biology. The company also outlined its participation at several other scientific events throughout July, including conferences in Montreal, London, and Anaheim.GlobeNewswireGlobal Cell Therapy Human Raw Materials Market Size/Share Worth USD 18.94 Billion by 2035 at a 16.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, GrHealthcare Foresights published a market research report projecting the global cell therapy human raw materials market will grow from USD 3.62 billion in 2025 to USD 18.94 billion by 2035, representing a compound annual growth rate of 16.3%. The report attributes growth to increasing cell therapy clinical trials, rising cancer and chronic disease prevalence, and expanded biomanufacturing capacity for CAR-T, stem cell, and regenerative medicine applications. Akadeum Life Sciences and BioIVT announced a strategic partnership in October 2025 to expand supply of leukopaks and T cells for cell therapy development.Business Wire BlogBioIVT Names Sean Downing, PhD, to Scientific Advisory BoardBioIVT announced the appointment of Sean Downing, PhD, to its Scientific Advisory Board to strengthen the company's scientific strategy around biospecimen quality and characterization. Downing brings expertise in translational science and biomarker strategy from previous roles across diagnostics, CROs, and biopharma, most recently serving as Vice President of Scientific Affairs at ICON plc. His appointment is intended to enhance integration of BioIVT's clinical data and biomarker capabilities to support more predictive research for drug and diagnostic developers.FinancialContent Business PageBioIVT Names Sean Downing, PhD, to Scientific Advisory BoardBioIVT, a biospecimen solutions provider for drug and diagnostic development, has appointed Sean Downing, PhD to its Scientific Advisory Board to advance the quality, characterization, and applicability of biospecimens. Downing brings extensive experience in biomarker and translational leadership from roles across diagnostics, CROs, and biopharma, having most recently served as Vice President of Scientific Affairs for ICON plc. His appointment is expected to enhance integration of clinical data and biomarker expertise to enable more predictive and clinically relevant research.Business Wire BlogSEQSTER Launches 1-Click Sites™ to Transform Clinical Sites into Research-Ready Data Collection Points: Names BioIVT as First Deployment PartnerSEQSTER PDM, Inc. launched "1-Click Sites," a new product enabling clinical sites to share patient-consented EHR data with trial sponsors without requiring software installation or health system contracts, eliminating months of traditional IT setup. The company announced a partnership with BioIVT, LLC as the first deployment partner, which will use the platform across its clinical sample collection network to provide richer longitudinal data for drug development decisions. The platform is designed to reduce activation timelines and expand the pool of research-ready locations for sponsors, CROs, and clinical networks.BioivtPress ReleasesBioIVT announced the acquisition of BeCytes Biotechnologies, a Spain-based company specializing in sourcing and processing human tissues and cells, to expand its biospecimen offerings and strengthen its presence in Europe. This strategic move aims to address the increasing demand for New Approach Methodologies (NAMs) and improve access to ethically sourced, high-quality biospecimens for biomedical research.Business Wire BlogBioIVT Welcomes BeCytes: Expanding Global Access to Ethically Sourced Human Biospecimens for ResearchBioIVT, a global biospecimen solutions provider for drug and diagnostic development, announced the acquisition of BeCytes Biotechnologies, a Barcelona-based company specializing in the collection, processing, and distribution of human tissues and cells for biomedical research. The acquisition strengthens BioIVT's European footprint and expands access to ethically sourced biospecimens, particularly primary hepatocytes, supporting New Approach Methodologies and ADME research. Founded in 2015, BeCytes brings expertise in tissue sourcing and primary cell isolation from human and animal sources, positioning BioIVT to meet growing global demand for NAMs in next-generation therapy development.Drug Discovery World (DDW)eBook: AI – Advancing drug discovery and developmentThis article is a promotional abstract for an eBook sponsored by BioIVT that explores the application of artificial intelligence in drug discovery and development. It highlights the rapid evolution of AI technologies, such as multimodal and agentic AI, and emphasizes the critical need for specialized skills to accelerate R&D workflows.PR NewswireAkadeum Life Sciences and BioIVT Collaborate to Provide Robust Starting Material to Developers of Cell Therapy ProductsAkadeum Life Sciences and BioIVT announced a collaboration to provide healthier T cells for cell therapy developers by combining Akadeum's Human T Cell Leukopak Isolation Kit-GMP with BioIVT's LEUKOMAX™ leukopaks. The in-bag microbubble-based separation enables faster cell separation workflows, reduced contamination risk, and more consistent results without requiring cell washing instrumentation. Both companies will continue generating additional workflow data to support more gentle approaches to cell therapy manufacturing.